Clinical Trials · NCT07284979

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Name: Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Semaglutide

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Kailera
Enrollment: 1,200
Start date: Dec 2025
Locations: 53 sites, 5 countries
Primary endpoint: Percent Change From Baseline in Body Weight at Week 76

View Semaglutide compound reference